Litcius/Paper detail

Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer

Jun Wu, Quan Wang, Xiaoqi Dong, Min Xu, Juliang Yang, Xiaoqing Yi, Biao Chen, Xiyuan Dong, Ying Wang, Xiaoding Lou, Fan Xia, Shixuan Wang, Jun Dai

2021Theranostics47 citationsDOIOpen Access PDF

Abstract

Our findings demonstrated the Py-TPE/siRNA@PMP as a promising agent for the highly efficient treatment of PTX-resistant cells and overcoming the shortage of chemotherapy in ovarian cancer.

Topics & Concepts

PaclitaxelProdrugOvarian cancerChemotherapyCancer researchBiocompatible materialCancerMedicineChemistryPharmacologyBiomedical engineeringInternal medicineNanoparticle-Based Drug DeliveryRNA Interference and Gene DeliveryNanoplatforms for cancer theranostics
Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer | Litcius